|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||24.03 - 24.03|
|52 Week Range||2.20 - 34.54|
|Beta (5Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature SANTA MONICA, Calif., June 16, 2020 -- BioVie, Inc. (OTCQB: BIVI) (“BioVie” or.
Novel BIV201 Formulation Shows Significant Improvements Over Industry TerlipressinPrefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity.
BIV201 (continuous infusion terlipressin) has not yet been approved for human use. The Company is planning to submit an amendment to its CMC package to the FDA for review and will test the new prefilled syringe in an upcoming US Phase 2b/3 clinical trial if cleared to proceed.